Tumors from patients with ccRCC-TT show a higher mutational burden and genomic instability; in addition, mutations in BAP1 and SETD2 are highly enriched in patients with ccRCC-TT. This evidence concerns the gene BAP1 and nonpapillary renal cell carcinoma.